Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results, Misses Expectations By $0.04 EPS

Key Points

• Oruka Therapeutics reported a quarterly loss of $0.55 per share, missing analyst expectations by $0.04.
• ORKA opened at $98.82 and has surged near its 12-month high of $100.34; analysts maintain a “Moderate Buy” consensus with an average price target of $134.30.
• The company remains a clinical-stage oncology biotech, with lead candidate ONCT-01 currently in Phase 1 trials for advanced solid tumors. Insiders have sold approximately $12.0 million of shares over the past 90 days.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04), FiscalAI reports.

Oruka Therapeutics Stock Performance

ORKA opened at $98.82 on Monday. Oruka Therapeutics has a 12 month low of $12.84 and a 12 month high of $100.34. The company has a market cap of $5.96 billion, a PE ratio of -50.94 and a beta of -0.34. The company has a 50 day moving average of $82.59 and a 200 day moving average of $60.25.

Analyst Ratings Changes

A number of research firms recently commented on ORKA. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the stock a "buy" rating in a research report on Monday, April 27th. HC Wainwright restated a "buy" rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Wedbush set a $165.00 price target on Oruka Therapeutics in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $134.30.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 9,999 shares of the stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the sale, the senior vice president owned 15,312 shares of the company's stock, valued at approximately $1,295,854.56. This represents a 39.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares of the company's stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 188,406 shares of company stock worth $12,019,683. Insiders own 23.49% of the company's stock.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its stake in Oruka Therapeutics by 777.1% during the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company's stock valued at $4,338,000 after acquiring an additional 126,803 shares in the last quarter. Virtus Investment Advisers LLC bought a new position in Oruka Therapeutics in the 4th quarter valued at $267,000. RTW Investments LP boosted its holdings in Oruka Therapeutics by 5.8% in the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock valued at $62,382,000 after purchasing an additional 112,499 shares during the period. Millennium Management LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at $1,780,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at $367,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source